Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

Strasbourg, France, August 19, 2015 – Transgene S.A. (Euronext: TNG) today announced that results, including more mature overall survival data, from the Phase 2b part of the Phase 2b/3 TIME trial with its immunotherapy candidate TG4010 in non-small cell lung cancer, will be presented at the 16th World Conference on Lung Cancer to be held in Denver, Colorado, USA, September 6-9, 2015. The conference is being hosted by the International Association for the Study of Lung Cancer (IASLC).

The presentation, TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results, will be given by Elisabeth Quoix, M.D., Ph.D., Head of the Department of Pulmonology at the University Hospital of Strasbourg and Coordinating Investigator of the TIME study, on Tuesday, September 8, 2015. The presentation will be part of Oral Session 18: Non PD1 Immunotherapy and Angiogenesis, which is part of the Treatment of Advanced Diseases – NSCLC track.

Abstracts will be available online on the IASLC website beginning on August 21, 2015 at 4 PM Pacific Time.

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.

Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant